Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Disease, Chronic Obstructive
Intervention: Atrovent® inhalets (Drug)
Phase: N/A
Status: Completed
Sponsored by: Boehringer Ingelheim
Summary
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long
term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Clinical Details
Official title: Postmarketing Surveillance (as Per §67(6)AMG [German Drug Law]) of Atrovent® in Chronic Obstructive Pulmonary Disease
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Investigator assessment of improvement of the clinical picture rated on a 6-point symptom profile
Secondary outcome: Assessment of efficacy by investigator on a 4-point scaleAssessment of efficacy by patient on a 4-point scale Assessment of tolerability by investigator on a 4-point scale Assessment of tolerability by patient on a 4-point scale Number of patients with adverse drug reactions
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Primarily patients of both gender, older than 40 years, who suffer from Chronic
Obstructive Pulmonary Disease
- Only patients who had not been treated with Atrovent® within the last year were to be
considered for inclusion
Exclusion Criteria:
• Contraindications listed in the Instructions for Use/Summary of Product Characteristics
for Atrovent® Inhalets
Locations and Contacts
Additional Information
Starting date: September 1999
Last updated: September 11, 2014
|